Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Current Leases: 2020-2025

Historic Current Leases for Arcutis Biotherapeutics (ARQT) over the last 5 years, with Mar 2025 value amounting to $842,000.

  • Arcutis Biotherapeutics' Current Leases rose 11.38% to $842,000 in Q1 2025 from the same period last year, while for Mar 2025 it was $842,000, marking a year-over-year increase of 11.38%. This contributed to the annual value of $820,000 for FY2024, which is 11.56% up from last year.
  • As of Q1 2025, Arcutis Biotherapeutics' Current Leases stood at $842,000, which was up 2.68% from $820,000 recorded in Q4 2024.
  • In the past 5 years, Arcutis Biotherapeutics' Current Leases ranged from a high of $842,000 in Q1 2025 and a low of $106,000 during Q2 2021.
  • Its 3-year average for Current Leases is $757,111, with a median of $756,000 in 2024.
  • Data for Arcutis Biotherapeutics' Current Leases shows a peak YoY surged of 856.25% (in 2021) over the last 5 years.
  • Arcutis Biotherapeutics' Current Leases (Quarterly) stood at $433,000 in 2021, then skyrocketed by 51.73% to $657,000 in 2022, then rose by 11.87% to $735,000 in 2023, then climbed by 11.56% to $820,000 in 2024, then increased by 11.38% to $842,000 in 2025.
  • Its Current Leases stands at $842,000 for Q1 2025, versus $820,000 for Q4 2024 and $798,000 for Q3 2024.